Rate of Requests to Return to Intravenous Biologic Disease-Modifying Antirheumatic Drug Therapy After an Intravenous-to-Subcutaneous Switch in Rheumatoid Arthritis
During the coronavirus disease 2019 (COVID-19) pandemic, many patients with rheumatoid arthritis (RA) were switched from intravenous (IV) to subcutaneous (SC) biologic therapies to reduce hospital visits. Although comparable efficacy between the 2 routes has been reported for abatacept and tocilizumab,1-4 real-world data on patient experience following an externally imposed treatment transition remain limited.
Authors
- S. Trijau
- Nathalie Balandraud (ORCID: https://orcid.org/0000-0002-3839-0185)
- Pierre Lafforgue (ORCID: https://orcid.org/0000-0001-8478-8023)
- Théo Wirth
- E. Fockens (ORCID: https://orcid.org/0000-0003-2533-2565)
- Thao Pham (ORCID: https://orcid.org/0000-0002-5978-0983)
- Lisa Diebold
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Aix-Marseille Université (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Hôpital Sainte-Marguerite (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- ARTHritEs, Microchimérisme et InflammationS (FR)
Publication Details
- Journal
- The Journal of Rheumatology
- Published
- 2026-11-15
- DOI
- https://doi.org/10.3899/jrheum.2026-0406
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00